145 related articles for article (PubMed ID: 16365543)
21. New treatments in ulcer healing and wound infection.
Edmonds M; Bates M; Doxford M; Gough A; Foster A
Diabetes Metab Res Rev; 2000; 16 Suppl 1():S51-4. PubMed ID: 11054889
[TBL] [Abstract][Full Text] [Related]
22. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel.
Castronuovo JJ; Ghobrial I; Giusti AM; Rudolph S; Smiell JM
Am J Surg; 1998 Aug; 176(2A Suppl):61S-67S. PubMed ID: 9777974
[TBL] [Abstract][Full Text] [Related]
23. Optimizing healing of the acute wound by minimizing complications.
Franz MG; Steed DL; Robson MC
Curr Probl Surg; 2007 Nov; 44(11):691-763. PubMed ID: 18036992
[No Abstract] [Full Text] [Related]
24. [Combined effect of Acticoat and VAC on wound healing].
Reeves I; Plourde M; Authier S; Doddridge C
Perspect Infirm; 2005; 2(5):10-5. PubMed ID: 15962530
[No Abstract] [Full Text] [Related]
25. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
Miller MS
J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
[TBL] [Abstract][Full Text] [Related]
26. Topical becaplermin improves outcomes in work related fingertip injuries.
Freedman BM; Oplinger EH; Freedman IS
J Trauma; 2005 Oct; 59(4):965-8. PubMed ID: 16374289
[TBL] [Abstract][Full Text] [Related]
27. Human plasma fibronectin potentiates the mitogenic activity of platelet-derived growth factor and complements its wound healing effects.
Larivière B; Rouleau M; Picard S; Beaulieu AD
Wound Repair Regen; 2003; 11(1):79-89. PubMed ID: 12581430
[TBL] [Abstract][Full Text] [Related]
28. The future of recombinant growth factors in wound healing.
Robson MC; Mustoe TA; Hunt TK
Am J Surg; 1998 Aug; 176(2A Suppl):80S-82S. PubMed ID: 9777977
[TBL] [Abstract][Full Text] [Related]
29. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
Fruhstorfer B
Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
[No Abstract] [Full Text] [Related]
30. Topical platelet-derived growth factor enhances wound closure in the absence of wound contraction: an experimental and clinical study.
Saba AA; Freedman BM; Gaffield JW; Mackay DR; Ehrlich HP
Ann Plast Surg; 2002 Jul; 49(1):62-6; discussion 66. PubMed ID: 12142597
[TBL] [Abstract][Full Text] [Related]
31. Platelet-derived growth factor for foot ulcerations. An effective adjunct to good wound care.
Watts SA
Adv Nurse Pract; 2001 Sep; 9(9):60-3. PubMed ID: 12420484
[No Abstract] [Full Text] [Related]
32. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
Persson U; Willis M; Odegaard K; Apelqvist J
Value Health; 2000; 3 Suppl 1():39-46. PubMed ID: 16464208
[TBL] [Abstract][Full Text] [Related]
33. Topical PDGF-BB results in limited healing in a patient with Werner's syndrome and chronic leg ulcers.
Wollina U; Gruner M; Koch A; Köstler E; Hubl W; Hanson NB; Oshima J
J Wound Care; 2004 Nov; 13(10):415-6. PubMed ID: 15575568
[TBL] [Abstract][Full Text] [Related]
34. The role of wound-bed preparation in managing chronic pressure ulcers.
Romanelli M; Mastronicola D
J Wound Care; 2002 Sep; 11(8):305-10. PubMed ID: 12360764
[TBL] [Abstract][Full Text] [Related]
35. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
Mustoe TA; Cutler NR; Allman RM; Goode PS; Deuel TF; Prause JA; Bear M; Serdar CM; Pierce GF
Arch Surg; 1994 Feb; 129(2):213-9. PubMed ID: 8304833
[TBL] [Abstract][Full Text] [Related]
36. [Growth factor for diabetic foot ulcer. How man amputations are preventable].
MMW Fortschr Med; 2000 Feb; 142(6):60. PubMed ID: 10832359
[No Abstract] [Full Text] [Related]
37. Healing and preventing the diabetic foot wound: where technology, economics and common sense converge.
Armstrong DG
Indian J Med Sci; 2007 Jun; 61(6):324-5. PubMed ID: 17558094
[No Abstract] [Full Text] [Related]
38. Re: Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers.
Brown GL
Ann Plast Surg; 1993 Feb; 30(2):192. PubMed ID: 8489189
[No Abstract] [Full Text] [Related]
39. Vacuum-assisted closure therapy.
O'Rourke ME
Clin J Oncol Nurs; 2006 Dec; 10(6):825-6. PubMed ID: 17193949
[No Abstract] [Full Text] [Related]
40. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.
Guzman-Gardearzabal E; Leyva-Bohorquez G; Salas-Colín S; Paz-Janeiro JL; Alvarado-Ruiz R; García-Salazar R
Adv Ther; 2000; 17(4):184-9. PubMed ID: 11185057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
